Multicancer Early Detection Tests: A State‐of‐the‐Art Review for Otolaryngologists
Abstract Objective To provide a review of the science and applicability of current multi‐cancer early detection (MCED) tests for otolaryngologists. Data Sources PubMed, clinicaltrials.gov, company websites. Review Methods Using PRISMA methodology, primary literature regarding MCED tests was queried...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | OTO Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/oto2.70040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850240449986428928 |
|---|---|
| author | Elena Kennedy Greg Durm Janice L. Farlow |
| author_facet | Elena Kennedy Greg Durm Janice L. Farlow |
| author_sort | Elena Kennedy |
| collection | DOAJ |
| description | Abstract Objective To provide a review of the science and applicability of current multi‐cancer early detection (MCED) tests for otolaryngologists. Data Sources PubMed, clinicaltrials.gov, company websites. Review Methods Using PRISMA methodology, primary literature regarding MCED tests was queried from April 26 to May 12, 2024 using MCED search terms. Ongoing clinical trials incorporating MCED screens were identified via the National Institutes of Health clinicaltrials.gov website. Company websites for available or upcoming MCED tests were reviewed. Conclusion Long‐term robust data regarding the performance characteristics, effects on clinical outcomes, and cost‐utility of MCED tests for head and neck cancer are currently lacking. Otolaryngologists should be aware of the implications of MCED tests as these assays become more widely used. Implications for Practice Although not FDA‐approved or covered by insurances at the time of writing of this manuscript, MCED testing is rapidly gaining interest, and patients with positive tests are presenting to otolaryngologists for evaluation. While MCED technologies hold great promise for early detection of disease and potential reduction of morbidity and mortality, more study is needed about their utility for head and neck cancer and optimal diagnostic workflows. |
| format | Article |
| id | doaj-art-03af90f9bcf44b60a39515d065c11cfa |
| institution | OA Journals |
| issn | 2473-974X |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | OTO Open |
| spelling | doaj-art-03af90f9bcf44b60a39515d065c11cfa2025-08-20T02:00:51ZengWileyOTO Open2473-974X2024-10-0184n/an/a10.1002/oto2.70040Multicancer Early Detection Tests: A State‐of‐the‐Art Review for OtolaryngologistsElena Kennedy0Greg Durm1Janice L. Farlow2Department of Otolaryngology–Head and Neck Surgery Indiana University School of Medicine Indianapolis Indiana USADepartment of Medicine, Division of Hematology/Oncology Indiana University School of Medicine Indianapolis Indiana USADepartment of Otolaryngology–Head and Neck Surgery Indiana University School of Medicine Indianapolis Indiana USAAbstract Objective To provide a review of the science and applicability of current multi‐cancer early detection (MCED) tests for otolaryngologists. Data Sources PubMed, clinicaltrials.gov, company websites. Review Methods Using PRISMA methodology, primary literature regarding MCED tests was queried from April 26 to May 12, 2024 using MCED search terms. Ongoing clinical trials incorporating MCED screens were identified via the National Institutes of Health clinicaltrials.gov website. Company websites for available or upcoming MCED tests were reviewed. Conclusion Long‐term robust data regarding the performance characteristics, effects on clinical outcomes, and cost‐utility of MCED tests for head and neck cancer are currently lacking. Otolaryngologists should be aware of the implications of MCED tests as these assays become more widely used. Implications for Practice Although not FDA‐approved or covered by insurances at the time of writing of this manuscript, MCED testing is rapidly gaining interest, and patients with positive tests are presenting to otolaryngologists for evaluation. While MCED technologies hold great promise for early detection of disease and potential reduction of morbidity and mortality, more study is needed about their utility for head and neck cancer and optimal diagnostic workflows.https://doi.org/10.1002/oto2.70040biomarkercancer screeninghead and neck cancerliquid biopsymulticancer early detection tests |
| spellingShingle | Elena Kennedy Greg Durm Janice L. Farlow Multicancer Early Detection Tests: A State‐of‐the‐Art Review for Otolaryngologists OTO Open biomarker cancer screening head and neck cancer liquid biopsy multicancer early detection tests |
| title | Multicancer Early Detection Tests: A State‐of‐the‐Art Review for Otolaryngologists |
| title_full | Multicancer Early Detection Tests: A State‐of‐the‐Art Review for Otolaryngologists |
| title_fullStr | Multicancer Early Detection Tests: A State‐of‐the‐Art Review for Otolaryngologists |
| title_full_unstemmed | Multicancer Early Detection Tests: A State‐of‐the‐Art Review for Otolaryngologists |
| title_short | Multicancer Early Detection Tests: A State‐of‐the‐Art Review for Otolaryngologists |
| title_sort | multicancer early detection tests a state of the art review for otolaryngologists |
| topic | biomarker cancer screening head and neck cancer liquid biopsy multicancer early detection tests |
| url | https://doi.org/10.1002/oto2.70040 |
| work_keys_str_mv | AT elenakennedy multicancerearlydetectiontestsastateoftheartreviewforotolaryngologists AT gregdurm multicancerearlydetectiontestsastateoftheartreviewforotolaryngologists AT janicelfarlow multicancerearlydetectiontestsastateoftheartreviewforotolaryngologists |